Vaxart (VXRT) to Release Quarterly Earnings on Thursday

Vaxart (NASDAQ:VXRT) is scheduled to be releasing its earnings data after the market closes on Thursday, August 8th. Analysts expect Vaxart to post earnings of $0.03 per share for the quarter.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Monday, May 13th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02. Vaxart had a negative return on equity of 121.06% and a negative net margin of 920.00%. The company had revenue of $2.18 million during the quarter. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vaxart Price Performance

Shares of NASDAQ VXRT opened at $0.62 on Friday. Vaxart has a 1-year low of $0.52 and a 1-year high of $1.54. The business has a 50-day moving average of $0.71 and a 200-day moving average of $0.92. The company has a market capitalization of $110.01 million, a price-to-earnings ratio of -1.17 and a beta of 0.65.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.